Shenzhen Xiankangda Biotechnology

Shenzhen Xiankangda Biotechnology is a high-tech biopharmaceutical company focused on the development of innovative cell therapies, particularly CAR-T and CAR-NK treatments for hematological malignancies and solid tumors. The company operates a comprehensive R&D infrastructure that includes platforms for antibody screening, viral vector production, and clinical-grade cell manufacturing. Xiankangda has advanced several candidates into investigator-initiated trials (IIT) and formal clinical phases, targeting well-known markers such as CD19 and BCMA, as well as solid tumor targets like Claudin-18.2. Beyond oncology, the company explores the application of mesenchymal stem cells (MSCs) for regenerative medicine and inflammatory diseases. Headquartered in Shenzhen, China, it aims to provide affordable and effective precision medicine solutions to patients globally.